{"id":10100,"date":"2026-04-01T06:13:37","date_gmt":"2026-04-01T11:13:37","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10100"},"modified":"2026-04-01T06:17:26","modified_gmt":"2026-04-01T11:17:26","slug":"nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","title":{"rendered":"Nanoscope Therapeutics nombra a Paul Hallen, veterano de la industria oftalmol\u00f3gica, como director de operaciones para impulsar la preparaci\u00f3n comercial global."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10100\" class=\"elementor elementor-10100\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 class=\"prntac\" style=\"text-align: center;\"><em>Veteran\u00a0ophthalmology executive with over 30 years of experience spanning R&amp;D, manufacturing, quality, commercial strategy, and franchise leadership<\/em><\/h3><h3 class=\"prntac\" style=\"text-align: center;\"><em>Exvicepresidente y director global de Retina en Alcon, con amplia experiencia en la creaci\u00f3n y expansi\u00f3n de franquicias oftalmol\u00f3gicas a nivel mundial.<\/em><\/h3><h3 class=\"prntac\" style=\"text-align: center;\"><em>Este nombramiento refuerza el liderazgo operativo a medida que Nanoscope avanza con MCO-010 (MOGENRY\u2122) hacia la presentaci\u00f3n de la solicitud de licencia biol\u00f3gica (BLA) y su posible comercializaci\u00f3n.<\/em><\/h3><p><span class=\"legendSpanClass\">DALLAS<\/span>,\u00a0<span class=\"legendSpanClass\">1 de abril de 2026<\/span>\u00a0 &#8212; <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy el nombramiento de Paul Hallen como Director de Operaciones.<\/p><p>Mr. Hallen brings over 30 years of broad ophthalmic leadership experience spanning marketing, sales, manufacturing, quality, research and development, and business strategy. He previously served as Vice President and Global Head of Retina at Alcon, where he helped lead one of the industry&#8217;s premier retina franchises, and also held a Vice President of R&amp;D role supporting internal development and external acquisition activities across Alcon&#8217;s business units. Mr. Hallen also served as a board member of US Retina.<\/p><p>As Chief Operating Officer, Mr. Hallen will lead Nanoscope&#8217;s global operations, including commercial readiness, supply chain, and cross-functional execution, as the company advances MCO-010 (MOGENRY\u2122) toward potential regulatory approval and launch.<\/p><p>&#8220;Paul is a highly respected ophthalmology leader with a rare combination of technical, operational, and commercial expertise,&#8221; said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope Therapeutics. &#8220;We have known and closely interacted with Paul for many years, and his appointment comes at an important time as we continue preparing for the potential commercialization of MOGENRY. His experience across retina, product development, and global launch planning will be invaluable as we work to bring our vision-restoring therapies to patients worldwide.&#8221;<\/p><p>&#8220;I am excited to join Nanoscope at such an important stage in its development,&#8221; said Paul Hallen, Chief Operating Officer of Nanoscope Therapeutics. &#8220;Nanoscope&#8217;s MOGENRY platform represents a fundamentally differentiated approach with the potential to restore vision for patients with severe retinal disease. I look forward to working with the team to help advance MOGENRY toward potential approval and to support the company&#8217;s operational and commercial readiness for the next stage of growth.&#8221;<\/p><p><b>Avanzando hacia la comercializaci\u00f3n<br class=\"dnr\" \/><\/b>Nanoscope continues to build clinical, regulatory, and scaled-up manufacturing momentum in support of MOGENRY for retinitis pigmentosa, including advancement of its rolling Biologics License Application in the United States. The company has also established a growing global regulatory foundation for MOGENRY, with Orphan Drug, Fast Track, and RMAT designations in the United States, Sakigake and Orphan Drug designations in Japan, five EMA Orphan designations across inherited retinal dystrophies, and, most recently, an Orphan drug designation for IRDs in Saudi Arabia. These milestones reflect the company&#8217;s expanding international regulatory pathway as it advances commercialization planning across key global markets.<\/p><p><b>Acerca de la plataforma MCO<br class=\"dnr\" \/><\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><b>Acerca de Nanoscope Therapeutics<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0A principios de 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience a principios de 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p><p><b>Contacto:<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics, Inc.<br class=\"dnr\" \/>+1 (817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Veteran\u00a0ophthalmology executive with over 30 years of experience spanning R&amp;D, manufacturing, quality, commercial strategy, and franchise leadership Former Vice President and Global Head of Retina at Alcon, with deep experience building and scaling global ophthalmic franchises Appointment strengthens operational leadership as Nanoscope advances MCO-010 (MOGENRY\u2122) toward BLA submission and potential commercialization DALLAS,\u00a0April 1, 2026\u00a0 &#8212; [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T11:13:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T11:17:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics nombra a Paul Hallen, veterano de la industria oftalmol\u00f3gica, como director de operaciones para impulsar su preparaci\u00f3n comercial global.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-04-01T11:13:37+00:00","article_modified_time":"2026-04-01T11:17:26+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"wordCount":733,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","url":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","name":"Nanoscope Therapeutics nombra a Paul Hallen, veterano de la industria oftalmol\u00f3gica, como director de operaciones para impulsar su preparaci\u00f3n comercial global.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10100"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10100\/revisions"}],"predecessor-version":[{"id":10105,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10100\/revisions\/10105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10101"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}